NCT06324812View on ClinicalTrials.gov

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Dermatitis, Atopic
Interventions
DRUG

Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)

subcutaneous injection，611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks

Trial Locations (1)

100003

RECRUITING

Beijing Children's Hospital, Beijing

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY